HomeCompareBVNRY vs EQR

BVNRY vs EQR: Dividend Comparison 2026

BVNRY yields 20.15% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $17.1K in total portfolio value· pulled ahead in Year 3
10 years
BVNRY
BVNRY
● Live price
20.15%
Share price
$9.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.3K
Annual income
$2.34
Full BVNRY calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — BVNRY vs EQR

📍 EQR pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBVNRYEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BVNRY + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BVNRY pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BVNRY
Annual income on $10K today (after 15% tax)
$1,712.85/yr
After 10yr DRIP, annual income (after tax)
$1.99/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $3,244.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BVNRY + EQR for your $10,000?

BVNRY: 50%EQR: 50%
100% EQR50/50100% BVNRY
Portfolio after 10yr
$31.9K
Annual income
$1,910.97/yr
Blended yield
5.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

BVNRY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
6.6
Piotroski
8/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BVNRY buys
0
EQR buys
0
No recent congressional trades found for BVNRY or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBVNRYEQR
Forward yield20.15%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.8%
Portfolio after 10y$23.3K$40.5K
Annual income after 10y$2.34$3,819.61
Total dividends collected$2.1K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold

Year-by-year: BVNRY vs EQR ($10,000, DRIP)

YearBVNRY PortfolioBVNRY Income/yrEQR PortfolioEQR Income/yrGap
1$11,708$1,007.56$11,248$547.57+$460.00BVNRY
2$13,078$551.22$12,701$666.53+$377.00BVNRY
3← crossover$14,282$287.74$14,405$814.59$123.00EQR
4$15,428$146.83$16,413$999.84$985.00EQR
5$16,582$74.12$18,795$1,232.92$2.2KEQR
6$17,780$37.23$21,639$1,527.95$3.9KEQR
7$19,043$18.65$25,057$1,903.80$6.0KEQR
8$20,386$9.34$29,197$2,385.87$8.8KEQR
9$21,817$4.67$34,250$3,008.70$12.4KEQR
10$23,347$2.34$40,467$3,819.61$17.1KEQR

BVNRY vs EQR: Complete Analysis 2026

BVNRYStock

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Full BVNRY Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this BVNRY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BVNRY vs SCHDBVNRY vs JEPIBVNRY vs OBVNRY vs KOBVNRY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.